Filing Flows › Staar Surgical (STAA) › Guidance & outlook
Staar Surgical (STAA) guidance and outlook
Staar Surgical's 10-Q filed Nov 4, 2026 makes 16 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 4, 2026
- We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.
- Such disclosures will be included on our website in the ‘Investor Relations’ sections.
- Further, while ICLs are intended to be permanent, our ICLs are reversible lens implants, meaning they can be removed by a doctor if desired.
- As a result of these factors, we do not expect to achieve our target gross margin of 75% in 2026, although we do expect improvement in the fourth quarter of 2026.
- We expect gross margin to improve going forward for several reasons.
- First, we expect manufacturing costs to decrease as production volumes rise in both the U.S. and Switzerland.
- Second, freight costs will improve once certain ERP enhancements are introduced to enable us to consolidate shipments to customers.
- Third, all new ICLs for China were manufactured in Switzerland starting the third quarter of 2026, we expect tariff costs will decline.
- Finally, we expect expiring product to decrease from the levels we saw during the first nine months of 2026.
- Through these concentrated efforts, the Company successfully met its sales targets for the quarter.
- While certain implementation-related issues persist, the Company has developed and implemented a comprehensive remediation plan and anticipates resolving the most significant issues by the end of 2026.
- The Company expects to continue to invest and add functionality to its systems.
Staar Surgical's latest quarter
Staar Surgical, Q3 2026: revenue $83.4M (-12% year over year), operating margin 6.5%, net earnings $5.6M, operating cash flow $27.3M. The chart follows the revenue to costs, profit and cash.
Questions
What does Staar Surgical expect?
We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the ‘Investor Relations’ sections. Further, while ICLs are intended to be permanent, our ICLs are reversible lens implants, meaning they can be removed by a doctor if desired.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.